Ketek — The FDA Perspective
- 19 April 2007
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (16) , 1675-1676
- https://doi.org/10.1056/nejmc076135
Abstract
In response to the article by Ross in this issue of the Journal,1 we wish to clarify how the Food and Drug Administration (FDA) reviewed Ketek (telithromycin). Although there are other statements or suggestions in the article that also need clarification, we address a few key points in the limited space available here.Keywords
This publication has 1 reference indexed in Scilit:
- The FDA and the Case of KetekNew England Journal of Medicine, 2007